XML 137 R105.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segments of Business and Geographic Areas - Sales by Segment of Business (Details) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2023 USD ($) | Oct. 01, 2023 USD ($) | Jul. 02, 2023 USD ($) | Apr. 02, 2023 USD ($) | Jan. 01, 2023 USD ($) | Oct. 02, 2022 USD ($) | Jul. 03, 2022 USD ($) | Apr. 03, 2022 USD ($) | Dec. 31, 2023 USD ($) segment | Jan. 01, 2023 USD ($) | Jan. 02, 2022 USD ($) Segment
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of segments |  |  |  |  |  |  |  |  | 2 |  | 3
Sales to Customers | $ 21,395 | $ 21,351 | $ 21,519 | $ 20,894 | $ 19,939 | $ 19,996 | $ 20,215 | $ 19,840 | $ 85,159 | $ 79,990 | $ 78,740
% Change |  |  |  |  |  |  |  |  | 6.50% | 1.60% |
Innovative Medicine |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | 13,722 | 13,893 | 13,731 | 13,413 | 13,163 | 13,214 | 13,317 | 12,869 | $ 54,759 | $ 52,563 | 51,680
% Change |  |  |  |  |  |  |  |  | 4.20% | 1.70% |
Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 18,052 | $ 16,935 | 16,750
% Change |  |  |  |  |  |  |  |  | 6.60% | 1.10% |
Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 4,418 | $ 5,449 | 5,825
% Change |  |  |  |  |  |  |  |  | (18.90%) | (6.50%) |
Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 7,140 | $ 6,893 | 6,988
% Change |  |  |  |  |  |  |  |  | 3.60% | (1.40%) |
Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 17,661 | $ 15,983 | 14,548
% Change |  |  |  |  |  |  |  |  | 10.50% | 9.90% |
Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,815 | $ 3,417 | 3,450
% Change |  |  |  |  |  |  |  |  | 11.60% | (1.00%) |
Innovative Medicine | Cardiovascular/Metabolism/Other |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,671 | $ 3,887 | 4,119
% Change |  |  |  |  |  |  |  |  | (5.50%) | (5.60%) |
MedTech |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | $ 7,673 | $ 7,458 | $ 7,788 | $ 7,481 | $ 6,776 | $ 6,782 | $ 6,898 | $ 6,971 | $ 30,400 | $ 27,427 | 27,060
% Change |  |  |  |  |  |  |  |  | 10.80% | 1.40% |
MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 6,350 | $ 4,300 | 3,971
% Change |  |  |  |  |  |  |  |  | 47.70% | 8.30% |
MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 8,942 | $ 8,587 | 8,588
% Change |  |  |  |  |  |  |  |  | 4.10% | 0.00% |
MedTech | Surgery |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 10,037 | $ 9,690 | 9,812
% Change |  |  |  |  |  |  |  |  | 3.60% | (1.20%) |
MedTech | Vision |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 5,072 | $ 4,849 | 4,688
% Change |  |  |  |  |  |  |  |  | 4.60% | 3.40% |
Remicade | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,839 | $ 2,343 | 3,190
% Change |  |  |  |  |  |  |  |  | (21.50%) | (26.60%) |
Simponi/Simponi Aria | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,197 | $ 2,184 | 2,276
% Change |  |  |  |  |  |  |  |  | 0.60% | (4.00%) |
Stelara | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 10,858 | $ 9,723 | 9,134
% Change |  |  |  |  |  |  |  |  | 11.70% | 6.50% |
Tremfya | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,147 | $ 2,668 | 2,127
% Change |  |  |  |  |  |  |  |  | 17.90% | 25.40% |
Other Immunology | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 11 | $ 17 | 24
% Change |  |  |  |  |  |  |  |  | (33.80%) | (28.20%) |
COVID-19 | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,117 | $ 2,179 | 2,385
% Change |  |  |  |  |  |  |  |  | (48.80%) | (8.60%) |
EDURANT/rilpivirine | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,150 | $ 1,008 | 994
% Change |  |  |  |  |  |  |  |  | 14.10% | 1.50% |
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,854 | $ 1,943 | 2,083
% Change |  |  |  |  |  |  |  |  | (4.60%) | (6.70%) |
Other Infectious Diseases | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 297 | $ 318 | 363
% Change |  |  |  |  |  |  |  |  | (6.70%) | (12.30%) |
CONCERTA/Methylphenidate | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 783 | $ 644 | 667
% Change |  |  |  |  |  |  |  |  | 21.60% | (3.50%) |
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 4,115 | $ 4,140 | 4,022
% Change |  |  |  |  |  |  |  |  | (0.60%) | 3.00% |
RISPERDAL CONSTA | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 689 | $ 374 | 224
% Change |  |  |  |  |  |  |  |  | 84.10% | 67.00% |
OTHER NEUROSCIENCE | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,553 | $ 1,734 | 2,074
% Change |  |  |  |  |  |  |  |  | (10.40%) | (16.40%) |
CARVYKTI | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 500 | $ 133 | 0
DARZALEX | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 9,744 | $ 7,977 | 6,023
% Change |  |  |  |  |  |  |  |  | 22.20% | 32.40% |
ERLEADA | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,387 | $ 1,881 | 1,291
% Change |  |  |  |  |  |  |  |  | 26.90% | 45.70% |
IMBRUVICA | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,264 | $ 3,784 | 4,369
% Change |  |  |  |  |  |  |  |  | (13.70%) | (13.40%) |
ZYTIGA/abiraterone acetate | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 887 | $ 1,770 | 2,297
% Change |  |  |  |  |  |  |  |  | (49.90%) | (22.90%) |
Other Oncology | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 879 | $ 438 | 568
% Change |  |  |  |  |  |  |  |  |  | (22.90%) |
OPSUMIT | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,973 | $ 1,783 | 1,819
% Change |  |  |  |  |  |  |  |  | 10.60% | (2.00%) |
UPTRAVI | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,582 | $ 1,322 | 1,237
% Change |  |  |  |  |  |  |  |  | 19.70% | 6.90% |
Other | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 260 | $ 313 | 395
% Change |  |  |  |  |  |  |  |  | (16.70%) | (20.80%) |
Other | Innovative Medicine | Cardiovascular/Metabolism/Other |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,306 | $ 1,414 | 1,682
% Change |  |  |  |  |  |  |  |  | (7.60%) | (15.90%) |
XARELTO | Innovative Medicine | Cardiovascular/Metabolism/Other |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,365 | $ 2,473 | 2,438
% Change |  |  |  |  |  |  |  |  | (4.40%) | 1.40% |
ELECTROPHYSIOLOGY | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 4,688 | $ 3,937 | 3,623
% Change |  |  |  |  |  |  |  |  | 19.10% | 8.70% |
Abiomed | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,306 | $ 31 | 0
Other Interventional Solutions | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 356 | $ 332 | 348
% Change |  |  |  |  |  |  |  |  | 7.10% | (4.60%) |
HIPS | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,560 | $ 1,514 | 1,480
% Change |  |  |  |  |  |  |  |  | 3.00% | 2.30% |
KNEES | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,456 | $ 1,359 | 1,325
% Change |  |  |  |  |  |  |  |  | 7.10% | 2.60% |
TRAUMA | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,979 | $ 2,871 | 2,885
% Change |  |  |  |  |  |  |  |  | 3.80% | (0.50%) |
SPINE,SPORTS & OTHER | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,947 | $ 2,843 | 2,898
% Change |  |  |  |  |  |  |  |  | 3.70% | (1.90%) |
ADVANCED | MedTech | Surgery |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 4,671 | $ 4,569 | 4,622
% Change |  |  |  |  |  |  |  |  | 2.20% | (1.10%) |
GENERAL | MedTech | Surgery |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 5,366 | $ 5,121 | 5,190
% Change |  |  |  |  |  |  |  |  | 4.80% | (1.30%) |
CONTACT LENSES/OTHER | MedTech | Vision |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,702 | $ 3,543 | 3,440
% Change |  |  |  |  |  |  |  |  | 4.50% | 3.00% |
SURGICAL | MedTech | Vision |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,370 | $ 1,306 | 1,248
% Change |  |  |  |  |  |  |  |  | 4.90% | 4.60% |
United States |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 46,444 | $ 41,981 | 40,640
% Change |  |  |  |  |  |  |  |  | 10.60% | 3.30% |
United States | Innovative Medicine |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 31,169 | $ 28,604 | 27,954
% Change |  |  |  |  |  |  |  |  | 9.00% | 2.30% |
United States | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 11,539 | $ 11,036 | 10,843
% Change |  |  |  |  |  |  |  |  | 4.60% | 1.80% |
United States | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,500 | $ 1,680 | 2,249
% Change |  |  |  |  |  |  |  |  | (10.70%) | (25.30%) |
United States | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 4,065 | $ 3,570 | 3,347
% Change |  |  |  |  |  |  |  |  | 13.90% | 6.70% |
United States | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 8,462 | $ 6,930 | 5,958
% Change |  |  |  |  |  |  |  |  | 22.10% | 16.30% |
United States | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,697 | $ 2,346 | 2,365
% Change |  |  |  |  |  |  |  |  | 15.00% | (0.80%) |
United States | Innovative Medicine | Cardiovascular/Metabolism/Other |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,906 | $ 3,042 | 3,192
% Change |  |  |  |  |  |  |  |  | (4.50%) | (4.70%) |
United States | MedTech |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 15,275 | $ 13,377 | 12,686
% Change |  |  |  |  |  |  |  |  | 14.20% | 5.40% |
United States | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,633 | $ 2,169 | 1,836
% Change |  |  |  |  |  |  |  |  | 67.50% | 18.20% |
United States | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 5,525 | $ 5,321 | 5,126
% Change |  |  |  |  |  |  |  |  | 3.80% | 3.80% |
United States | MedTech | Surgery |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 4,031 | $ 3,897 | 3,867
% Change |  |  |  |  |  |  |  |  | 3.40% | 0.80% |
United States | MedTech | Vision |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,086 | $ 1,990 | 1,857
% Change |  |  |  |  |  |  |  |  | 4.80% | 7.20% |
United States | Remicade | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,143 | $ 1,417 | 2,019
% Change |  |  |  |  |  |  |  |  | (19.30%) | (29.80%) |
United States | Simponi/Simponi Aria | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,124 | $ 1,166 | 1,127
% Change |  |  |  |  |  |  |  |  | (3.60%) | 3.50% |
United States | Stelara | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 6,966 | $ 6,388 | 5,938
% Change |  |  |  |  |  |  |  |  | 9.00% | 7.60% |
United States | Tremfya | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,147 | $ 1,844 | 1,503
% Change |  |  |  |  |  |  |  |  | 16.50% | 22.70% |
United States | Other Immunology | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 11 | $ 17 | 21
% Change |  |  |  |  |  |  |  |  | (33.80%) | (18.40%) |
United States | COVID-19 | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 0 | $ 120 | 634
% Change |  |  |  |  |  |  |  |  |  | (81.10%) |
United States | EDURANT/rilpivirine | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 35 | $ 36 | 41
% Change |  |  |  |  |  |  |  |  | (3.70%) | (10.80%) |
United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,446 | $ 1,494 | 1,508
% Change |  |  |  |  |  |  |  |  | (3.20%) | (1.00%) |
United States | Other Infectious Diseases | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 19 | $ 30 | 66
% Change |  |  |  |  |  |  |  |  | (34.50%) | (55.50%) |
United States | CONCERTA/Methylphenidate | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 230 | $ 151 | 172
% Change |  |  |  |  |  |  |  |  | 52.50% | (12.50%) |
United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,897 | $ 2,714 | 2,550
% Change |  |  |  |  |  |  |  |  | 6.70% | 6.50% |
United States | RISPERDAL CONSTA | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 589 | $ 328 | 198
% Change |  |  |  |  |  |  |  |  | 79.70% | 65.70% |
United States | OTHER NEUROSCIENCE | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 349 | $ 376 | 427
% Change |  |  |  |  |  |  |  |  | (7.30%) | (11.90%) |
United States | CARVYKTI | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 469 | $ 133 | 0
United States | DARZALEX | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 5,277 | $ 4,210 | 3,169
% Change |  |  |  |  |  |  |  |  | 25.40% | 32.80% |
United States | ERLEADA | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,065 | $ 968 | 813
% Change |  |  |  |  |  |  |  |  | 10.00% | 19.20% |
United States | IMBRUVICA | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,051 | $ 1,390 | 1,747
% Change |  |  |  |  |  |  |  |  | (24.40%) | (20.40%) |
United States | ZYTIGA/abiraterone acetate | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 50 | $ 74 | 119
% Change |  |  |  |  |  |  |  |  | (32.10%) | (37.80%) |
United States | Other Oncology | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 549 | $ 156 | 110
% Change |  |  |  |  |  |  |  |  |  | 41.80% |
United States | OPSUMIT | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,292 | $ 1,132 | 1,147
% Change |  |  |  |  |  |  |  |  | 14.10% | (1.30%) |
United States | UPTRAVI | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,326 | $ 1,104 | 1,056
% Change |  |  |  |  |  |  |  |  | 20.10% | 4.50% |
United States | Other | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 79 | $ 110 | 163
% Change |  |  |  |  |  |  |  |  | (28.60%) | (32.30%) |
United States | Other | Innovative Medicine | Cardiovascular/Metabolism/Other |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 541 | $ 569 | 754
% Change |  |  |  |  |  |  |  |  | (5.00%) | (24.50%) |
United States | XARELTO | Innovative Medicine | Cardiovascular/Metabolism/Other |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,365 | $ 2,473 | 2,438
% Change |  |  |  |  |  |  |  |  | (4.40%) | 1.40% |
United States | ELECTROPHYSIOLOGY | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,458 | $ 2,036 | 1,730
% Change |  |  |  |  |  |  |  |  | 20.70% | 17.70% |
United States | Abiomed | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,066 | $ 31 | 0
United States | Other Interventional Solutions | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 109 | $ 102 | 106
% Change |  |  |  |  |  |  |  |  | 6.70% | (3.80%) |
United States | HIPS | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 996 | $ 943 | 878
% Change |  |  |  |  |  |  |  |  | 5.60% | 7.30% |
United States | KNEES | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 896 | $ 851 | 787
% Change |  |  |  |  |  |  |  |  | 5.30% | 8.20% |
United States | TRAUMA | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,949 | $ 1,882 | 1,819
% Change |  |  |  |  |  |  |  |  | 3.60% | 3.50% |
United States | SPINE,SPORTS & OTHER | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,684 | $ 1,645 | 1,642
% Change |  |  |  |  |  |  |  |  | 2.40% | 0.20% |
United States | ADVANCED | MedTech | Surgery |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,833 | $ 1,784 | 1,761
% Change |  |  |  |  |  |  |  |  | 2.80% | 1.30% |
United States | GENERAL | MedTech | Surgery |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,198 | $ 2,113 | 2,105
% Change |  |  |  |  |  |  |  |  | 4.00% | 0.40% |
United States | CONTACT LENSES/OTHER | MedTech | Vision |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,626 | $ 1,522 | 1,398
% Change |  |  |  |  |  |  |  |  | 6.80% | 8.90% |
United States | SURGICAL | MedTech | Vision |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 460 | $ 468 | 459
% Change |  |  |  |  |  |  |  |  | (1.80%) | 2.00% |
Non-US |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 38,715 | $ 38,009 | 38,100
% Change |  |  |  |  |  |  |  |  | 1.90% | (0.20%) |
Non-US | Innovative Medicine |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 23,590 | $ 23,959 | 23,726
% Change |  |  |  |  |  |  |  |  | (1.50%) | 1.00% |
Non-US | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 6,513 | $ 5,899 | 5,907
% Change |  |  |  |  |  |  |  |  | 10.40% | (0.10%) |
Non-US | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,918 | $ 3,769 | 3,576
% Change |  |  |  |  |  |  |  |  | (22.60%) | 5.40% |
Non-US | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,076 | $ 3,323 | 3,641
% Change |  |  |  |  |  |  |  |  | (7.50%) | (8.70%) |
Non-US | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 9,199 | $ 9,052 | 8,590
% Change |  |  |  |  |  |  |  |  | 1.60% | 5.40% |
Non-US | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,117 | $ 1,071 | 1,085
% Change |  |  |  |  |  |  |  |  | 4.30% | (1.30%) |
Non-US | Innovative Medicine | Cardiovascular/Metabolism/Other |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 765 | $ 845 | 927
% Change |  |  |  |  |  |  |  |  | (9.40%) | (8.90%) |
Non-US | MedTech |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 15,125 | $ 14,050 | 14,374
% Change |  |  |  |  |  |  |  |  | 7.70% | (2.30%) |
Non-US | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,717 | $ 2,131 | 2,135
% Change |  |  |  |  |  |  |  |  | 27.50% | (0.20%) |
Non-US | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,417 | $ 3,267 | 3,462
% Change |  |  |  |  |  |  |  |  | 4.60% | (5.60%) |
Non-US | MedTech | Surgery |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 6,006 | $ 5,793 | 5,945
% Change |  |  |  |  |  |  |  |  | 3.70% | (2.60%) |
Non-US | MedTech | Vision |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,986 | $ 2,859 | 2,831
% Change |  |  |  |  |  |  |  |  | 4.50% | 1.00% |
Non-US | Remicade | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 549 | $ 722 | 935
% Change |  |  |  |  |  |  |  |  | (23.90%) | (22.80%) |
Non-US | Simponi/Simponi Aria | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,073 | $ 1,017 | 1,148
% Change |  |  |  |  |  |  |  |  | 5.40% | (11.40%) |
Non-US | Stelara | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,892 | $ 3,335 | 3,196
% Change |  |  |  |  |  |  |  |  | 16.70% | 4.40% |
Non-US | Tremfya | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 999 | $ 824 | 624
% Change |  |  |  |  |  |  |  |  | 21.20% | 32.00% |
Non-US | Other Immunology | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 0 | $ 0 | 3
% Change |  |  |  |  |  |  |  |  | 0.00% |  |
Non-US | COVID-19 | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,117 | $ 2,059 | 1,751
% Change |  |  |  |  |  |  |  |  | (45.80%) | 17.60% |
Non-US | EDURANT/rilpivirine | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,115 | $ 972 | 953
% Change |  |  |  |  |  |  |  |  | 14.80% | 2.00% |
Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 408 | $ 449 | 575
% Change |  |  |  |  |  |  |  |  | (9.20%) | (21.90%) |
Non-US | Other Infectious Diseases | Innovative Medicine | Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 278 | $ 289 | 297
% Change |  |  |  |  |  |  |  |  | (3.80%) | (2.60%) |
Non-US | CONCERTA/Methylphenidate | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 554 | $ 493 | 495
% Change |  |  |  |  |  |  |  |  | 12.20% | (0.40%) |
Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,218 | $ 1,426 | 1,472
% Change |  |  |  |  |  |  |  |  | (14.60%) | (3.10%) |
Non-US | RISPERDAL CONSTA | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 100 | $ 46 | 26
% Change |  |  |  |  |  |  |  |  |  | 76.90% |
Non-US | OTHER NEUROSCIENCE | Innovative Medicine | Neuroscience |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,204 | $ 1,358 | 1,647
% Change |  |  |  |  |  |  |  |  | (11.30%) | (17.50%) |
Non-US | CARVYKTI | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 30 | $ 0 | 0
Non-US | DARZALEX | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 4,467 | $ 3,767 | 2,854
% Change |  |  |  |  |  |  |  |  | 18.60% | 32.00% |
Non-US | ERLEADA | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,322 | $ 913 | 478
% Change |  |  |  |  |  |  |  |  | 44.80% |  |
Non-US | IMBRUVICA | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,214 | $ 2,394 | 2,622
% Change |  |  |  |  |  |  |  |  | (7.50%) | (8.70%) |
Non-US | ZYTIGA/abiraterone acetate | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 837 | $ 1,696 | 2,178
% Change |  |  |  |  |  |  |  |  | (50.70%) | (22.10%) |
Non-US | Other Oncology | Innovative Medicine | Oncology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 330 | $ 283 | 458
% Change |  |  |  |  |  |  |  |  | 16.90% | (38.20%) |
Non-US | OPSUMIT | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 681 | $ 651 | 672
% Change |  |  |  |  |  |  |  |  | 4.60% | (3.20%) |
Non-US | UPTRAVI | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 255 | $ 218 | 181
% Change |  |  |  |  |  |  |  |  | 17.30% | 20.40% |
Non-US | Other | Innovative Medicine | Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 182 | $ 202 | 232
% Change |  |  |  |  |  |  |  |  | (10.30%) | (12.80%) |
Non-US | Other | Innovative Medicine | Cardiovascular/Metabolism/Other |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 765 | $ 845 | 927
% Change |  |  |  |  |  |  |  |  | (9.40%) | (8.80%) |
Non-US | XARELTO | Innovative Medicine | Cardiovascular/Metabolism/Other |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 0 | $ 0 | 0
% Change |  |  |  |  |  |  |  |  | 0.00% | 0.00% |
Non-US | ELECTROPHYSIOLOGY | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,230 | $ 1,901 | 1,893
% Change |  |  |  |  |  |  |  |  | 17.30% | 0.40% |
Non-US | Abiomed | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 240 | $ 0 | 0
Non-US | Other Interventional Solutions | MedTech | Interventional Solutions |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 247 | $ 230 | 242
% Change |  |  |  |  |  |  |  |  | 7.30% | (5.00%) |
Non-US | HIPS | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 564 | $ 571 | 602
% Change |  |  |  |  |  |  |  |  | (1.20%) | (5.10%) |
Non-US | KNEES | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 559 | $ 508 | 538
% Change |  |  |  |  |  |  |  |  | 10.20% | (5.70%) |
Non-US | TRAUMA | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,030 | $ 989 | 1,066
% Change |  |  |  |  |  |  |  |  | 4.10% | (7.20%) |
Non-US | SPINE,SPORTS & OTHER | MedTech | Orthopaedics |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 1,263 | $ 1,198 | 1,256
% Change |  |  |  |  |  |  |  |  | 5.40% | (4.60%) |
Non-US | ADVANCED | MedTech | Surgery |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,837 | $ 2,785 | 2,861
% Change |  |  |  |  |  |  |  |  | 1.90% | (2.60%) |
Non-US | GENERAL | MedTech | Surgery |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 3,168 | $ 3,008 | 3,085
% Change |  |  |  |  |  |  |  |  | 5.30% | (2.50%) |
Non-US | CONTACT LENSES/OTHER | MedTech | Vision |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 2,076 | $ 2,022 | 2,043
% Change |  |  |  |  |  |  |  |  | 2.70% | (1.00%) |
Non-US | SURGICAL | MedTech | Vision |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 910 | $ 837 | 788
% Change |  |  |  |  |  |  |  |  | 8.60% | 6.20% |
UNITED STATES Exports | Remicade | Innovative Medicine | Immunology |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 147 | $ 204 | $ 236
% Change |  |  |  |  |  |  |  |  | (28.00%) | (13.60%) |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18 + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CARVYKTIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ErleadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ELECTROPHYSIOLOGYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_AbiomedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |